0907 GMT - AstraZeneca can meet its 2030 revenue target even if a highly anticipated lung-cancer clinical trial fails, and continue to grow thereafter, analysts at UBS say in a research note. A pullback in the U.K. drugmaker's stock after recent failures of late-stage studies and merger speculation seems overdone, according to UBS. There is some degree of uncertainty over whether AstraZeneca's lung-cancer study will lead to a clinically meaningful result, but a miss wouldn't compromise the company's $80 billion 2030 revenue target, the analysts say. The company can grow beyond 2030 despite some major drugs going off patent and still has drugs in its pipeline with potential to generate multibillion-dollar annual sales, they add. UBS cuts its target price for the stock to 152 pounds from 176 pounds. Shares rise 0.7% to 122 pounds.